Lamivudine

Drug Profile

Lamivudine

Alternative Names: 3TC; 3TC-HBV; BCH 189; BCH 790; Epivir; Epivir-HBV; GR 103665; GR 109714X; Heptodin®; Heptovir; NGPB 21; Victron; Zeffix; Zefix

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Ajinomoto; Aspen Pharmacare; GlaxoSmithKline; GlaxoSmithKline KK
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B; HIV infections; Liver cirrhosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Jun 2012 First generic equivalent available in United Kingdom and Italy for HIV infections
  • 16 Sep 2005 Registered for Cirrhosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top